GV 2016 GP, L.L.C. 4
4 · Arcus Biosciences, Inc. · Filed Mar 19, 2018
Insider Transaction Report
Form 4
GV 2016 GP, L.L.C.
10% Owner
Transactions
- Conversion
Series B Convertible Preferred Stock
2018-03-19−3,125,312→ 0 total(indirect: By GV 2016, L.P.)→ Common Stock (3,125,312 underlying) - Conversion
Common Stock
2018-03-19+3,125,312→ 3,125,312 total(indirect: By GV 2016, L.P.)
Footnotes (3)
- [F1]The total represents shares received upon conversion of shares of Series B Convertible Preferred Stock.
- [F2]The reported security is directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2016 GP, L.P., GV 2016 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- [F3]The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.